January 4, 2023
Life Sciences
  • Gilead Sciences Inc. and EVOQ Therapeutics Inc. are partnering to develop autoimmune disorder treatments in a deal worth up to $658.5 million. The companies will collaborate on preclinical work for rheumatoid arthritis and lupus treatments, and Gilead will then conduct clinical development and the commercialization of candidates. (Article here)